Results 111 to 120 of about 7,888 (200)

[alarmin].

Arerugi = [Allergy], 2015
openaire   +3 more sources

When Alarmins Are “Therapeutic”

HemaSphere, 2020
openaire   +3 more sources

Airway epithelial dysfunction in asthma pathogenesis: epigenetic mechanisms, inflammatory crosstalk, and therapeutic opportunities. [PDF]

Front Allergy
Zhang B, Song G, Sun M, Zhang Y, Ren M.
europepmc   +1 more source

Innate immune regulation of adaptive immunity: mechanisms, implications, and bias. [PDF]

Front Immunol
Zhang Y, Qin Y, Cheng Z.
europepmc   +1 more source

Eosinophil-Epithelial Cell Crosstalk at Mucosal Barriers: From Homeostatic Regulation to Disease Pathogenesis. [PDF]

Cells
Lee J, Kim E.
europepmc   +1 more source

Circulating levels of high mobility group box-1 and nucleophosmin/B23 proteins and clinical significance in debut non-small cell lung cancer patients. [PDF]

Sci Rep
Tan H, Liu L, Yi Y, Valenzuela C, Zhao Q, Zhang Z, Li W, Perea SE, Perera Y.   +8 more
europepmc   +1 more source

Targeting the Epithelial Alarmin Axis with Biomedical Nanoparticles: A New Frontier in Allergic Asthma Therapy. [PDF]

Int J Nanomedicine
Yang Y.
europepmc   +1 more source

Blimp-1 integrates alarmin signals in ILC2s and drives proinflammatory functions required for type 2 immunity. [PDF]

J Exp Med
Forster PM, Preußer A, Yano H, Deshpande D, Zhang W, Kowalczyk A, Velleman L, Dubik MO, Uddin J, Emanuel ER, Leclère PS, Mertens R, Gao X, Kofoed-Branzk M, Hauser AE, Mittrücker HW, Diefenbach A, Artis D, Klose CSN.   +18 more
europepmc   +1 more source

Tezepelumab: redefining TSLP blockade in severe asthma through mechanistic precision and translational pharmacology. [PDF]

Front Pharmacol
Mansour GK, Kumar S, Sukkarieh HH.
europepmc   +1 more source

Structural and functional evolution of IL-1 targeting: From systemic neutralization to bioengineered nanotherapies. [PDF]

Mater Today Bio
Yang L, Chen G, Lyu Z.
europepmc   +1 more source